Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 20656472
Habib SL, et al. (2010) Novel mechanism of reducing tumourigenesis: upregulation of the DNA repair enzyme OGG1 by rapamycin-mediated AMPK activation and mTOR inhibition. Eur J Cancer 46, 2806-20 20656472
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T183-p - AMPKA1 (human)
Modsite: sDGEFLRtsCGsPNy SwissProt Entrez-Gene
Orthologous residues
AMPKA1 (human): T183‑p, AMPKA1 iso2 (human): T198‑p, AMPKA1 (mouse): T183‑p, AMPKA1 (rat): T183‑p, AMPKA1 (fruit fly): T184‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  kidney cancer
Relevant cell lines - cell types - tissues:  'kidney, tubule' [TSC2 (mouse), homozygous knockout], 786-O (renal), HK2 (epithelial), MEF (fibroblast) [TSC2 (mouse), heterozygous knockout]
Cellular systems studied:  cell lines, primary cells, tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
rapamycin increase HK2 and 786-O cells
acadesine increase 786-O cells

T412-p - p70S6K (human)
Modsite: NQVFLGFtyVAPsVL SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  kidney cancer
Relevant cell lines - cell types - tissues:  'kidney, tubule' [TSC2 (mouse), homozygous knockout], 786-O (renal), HK2 (epithelial), MEF (fibroblast) [TSC2 (mouse), heterozygous knockout]
Cellular systems studied:  cell lines, primary cells, tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
rapamycin decrease HK2 and 786-O cells
acadesine decrease 786-O cells

S79-p - ACC1 (mouse)
Modsite: FHMRSsMsGLHLVKQ SwissProt Entrez-Gene
Orthologous residues
ACC1 (human): S80‑p, ACC1 iso2 (human): S22‑p, ACC1 iso4 (human): S117‑p, ACC1 (mouse): S79‑p, ACC1 iso2 (mouse): S117‑p, ACC1 (rat): S79‑p, ACC1 iso2 (rat): S79‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  kidney cancer
Relevant cell lines - cell types - tissues:  'kidney, tubule' [TSC2 (mouse), homozygous knockout], 786-O (renal), HK2 (epithelial), MEF (fibroblast) [TSC2 (mouse), heterozygous knockout]
Cellular systems studied:  cell lines, primary cells, tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
rapamycin increase TSC2 +/- cells, in vivo kidney cortex TSC2 +/-
AMPKA1 (human) decrease dominant negative AMPK, TCSC2 +/- cells
acadesine AMPKA1 (human) increase

T183-p - AMPKA1 (mouse)
Modsite: sDGEFLRtsCGsPNY SwissProt Entrez-Gene
Orthologous residues
AMPKA1 (human): T183‑p, AMPKA1 iso2 (human): T198‑p, AMPKA1 (mouse): T183‑p, AMPKA1 (rat): T183‑p, AMPKA1 (fruit fly): T184‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  kidney cancer
Relevant cell lines - cell types - tissues:  'kidney, tubule' [TSC2 (mouse), homozygous knockout], 786-O (renal), HK2 (epithelial), MEF (fibroblast) [TSC2 (mouse), heterozygous knockout]
Cellular systems studied:  cell lines, primary cells, tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
rapamycin increase TSC2 +/+, +/-, -/- cells, in vivo kidney cortex TSC2 +/-
acadesine increase TSC2+/-, -/- cells
glucose decrease TSC2 +/- cells
rapamycin glucose inhibit treatment-induced decrease TSC2 +/- cells
AMPKA1 (human) decrease dominant negative AMPK, TSC2 +/- cells
acadesine AMPKA1 (human) increase

T412-p - p70S6K (mouse)
Modsite: NQVFLGFtYVAPSVL SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  kidney cancer
Relevant cell lines - cell types - tissues:  'kidney, tubule' [TSC2 (mouse), homozygous knockout], 786-O (renal), HK2 (epithelial), MEF (fibroblast) [TSC2 (mouse), heterozygous knockout]
Cellular systems studied:  cell lines, primary cells, tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
rapamycin decrease TSC2 +/+, +/-, -/- cells, in vivo kidney cortex TSC2 +/-
acadesine decrease TSC2+/-, -/- cells
glucose increase TSC2 +/- cells
rapamycin glucose inhibit treatment-induced increase TSC2 +/- cells
p70S6K (human) decrease dominant negative p70S6K, TSC2 +/- cells